Treadwell Therapeutics, Inc.

In the previous installment of Scrip Asks…What Does 2023 Hold For Biopharma? , we asked what technological advance would have the biggest impact on biopharma in 2023. Artificial intelligence was a fe

Conditions look ripe for an uptick in M&A this year after a fairly quiet 2022, while other types of strategic deals are also expected to increase in the face of a challenging funding situation for bio

Lysogene Licenses Gene Therapy Candidate From Yeda Research Advancing a collaboration inked in July 2020, gene therapy specialist Lysogene SA said on 12 April that it is taking its option to license

Glenmark Pharmaceuticals Limited , is progressing its small-molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor, GRC 54276, joining a select but growing list of firms pursuing the promising th